Congrats to South Carolina Women's Basketball & Kansas Men’s Basketball for such remarkable heart-stopping wins. Great games, already can't wait for next season. Looking forward to MLB starting this week too! #MarchMadness

As a founder of OTS & former President, I am proud to serve on the scientific advisory council & in joining other scientific orgs in seeking to help Ukrainian scientists & their families. The Oligonucleotide Therapeutics Society has a great number of resources & we are here to help in any way possible

I am proud of our employees for their dedication to creating a future where no one lives with devastating neurological diseases like Parkinson's & I whole heartedly believe it is with Ionis' revolutionary antisense technology that makes this hope possible

Volunteering is very near & dear to me. At Ionis, we benefit from two paid days off a year to volunteer in any capacity. We have such great interest in this program & I'm grateful for all our incredible employees who are making huge impacts in our community

One of the highlights of my year is to meet with our college summer interns & watch them grow into young leaders. We have a great program that I'm lucky to be involved in & I'm looking forward to meeting the new cohort soon. Be sure to check our website for future opportunities

Thrilled with the news we shared today about our potential transformational medicine, tofersen for patients suffering from ALS caused by SOD1 mutations. Striking results across many meaningful clinical endpoints! tinyurl.com/IonsP3ALS060322

This night. Unreal. Can’t believe I got myself together after that ovation for Chris Snow. It was a core memory kind of night, friends. So grateful. And our our little Crowchild Twin Arena skaters giving fellow CTA skater Cale Makar the Norris? incredible. ❤️

Really thrilled with our Phase 3 results for eplontersen in TTR polyneuropathy patients announced this week Impressive efficacy and tolerability across all measures. Another potential breakthrough for patients. tinyurl.com/eplontersenPh3…

Impressive activity for our novel HBV therapy. Can you say “Functional Cures”? Onwards to Phase 3! tinyurl.com/positivePh2bda…

Very pleased to have announced today our plans to build a new state of the art manufacturing facility for Ionis. Sets Ionis up well to sustainably deliver life-changing medicines to patients from our industry-leading pipeline for many years to come. ir.ionispharma.com/news-releases/…

Very pleased with the FDA advisory panel’s unanimous vote in support of tofersen’s accelerated approval for SOD1 ALS. A great day for ALS patients and the ALS community!

Pleased to very successful Phase 3 outcome for our TTR amyloid ASO silencer for ATTRv-PN. Looking forward to our late-breaker presentation at AAN in April! ir.ionispharma.com/news-releases/…

What a week for IONS and our patients! Reported strong Ph3 data for eplontersen in ATTRv-PN with potential best-in-class profile & now today's FDA approval of QALSODY (tofersen) for SOD1-ALS.  A breakthrough for ALS patients. So proud of my Ionis team! tinyurl.com/Qalsody

At Ionis, we work every day to give people not only hope, but also much more time with their families to enjoy life. Proud to be partnered with Biogen to deliver Qalsody to patients with SOD1-ALS. kptv.com/2023/06/14/fir…

Dinner with my long-time friend & science colleague Dr. Jeff Kelly, discoverer of tafamidis. It was great sharing stories about innovation in drug development for ATTR amyloidosis and other diseases. #innovation #research #leadership

Today, we shared positive preliminary findings from Part 1 of the ongoing HALOS Phase 1/2a trial of ION582, an investigational treatment for Angelman syndrome. Updates were presented at the Foundation for Angelman Syndrome Therapeutics Summit. Learn more: ow.ly/jUE450Q6FBo

We look forward to sharing new Phase 3 NEURO-TTRansform subgroup data at the 2024 International Symposium on Amyloidosis (ISA) for our medicine for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Read more: ir.ionispharma.com/news-releases/… $IONS

We’re proud to share that NEJM today published the positive Phase 3 OASIS-HAE results for our investigational medicine for the treatment of hereditary angioedema (#HAE), which were simultaneously presented at #EAACIcongress. Read the full article: nejm.org/doi/full/10.10….

"I always hesitate to bring my political beliefs into this space. I don’t think my listeners would expect that from me and some of you will find it disappointing: not what you were looking for... " [1 of 2]

Looking forward to participating on the Evolving Landscape of Drug Discovery Targeting RNA panel at Biocom California’s Global Life Science Partnering & Investor Conference in La Jolla. Join me at #BiocomGPIC from February 25 – 27. app.sosha.ai/s/FINuvCwH